Sabby Management’s Parnell Pharmaceuticals Holdings Ltd PARN Stock Holding History

Sabby Management’s Portfolio PARN Stock Details PARN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-170,000	Closed	-$143K	–	248
2017 Q2	$143K	Sell	170,000 -33,549	-16%	-$28.2K	0.01%	189
2017 Q1	$181K	Buy	203,549 +3,000	+1%	+$2.67K	0.01%	219
2016 Q4	$138K	Sell	200,549 -169,151	-46%	-$201K	0.01%	258
2016 Q3	$532K	Sell	369,700 -19,700	-5%	-$30.5K	0.02%	219
2016 Q2	$635K	Buy	+389,400	New	+$716K	0.03%	198

Other funds holding PARN

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Sabby Management's PARN Position: Q3 2017 in Review

Sabby Management sold out of Parnell Pharmaceuticals Holdings Ltd (PARN) in Q3 2017, closing a stake of 170,000 shares — an estimated $143K sold.

Sabby Management first reported a position in PARN in Q2 2016 and held it in 5 quarters. The position peaked at $635K in Q2 2016. 2 funds tracked by Wall St. Rank hold PARN as of Q3 2017.

Sabby Management reported no remaining Parnell Pharmaceuticals Holdings Ltd position as of Q3 2017 after selling out during the quarter.
Sabby Management sold 170,000 Parnell Pharmaceuticals Holdings Ltd shares in Q3 2017, an estimated $143K.
Sabby Management first reported a position in Parnell Pharmaceuticals Holdings Ltd in Q2 2016 and held it in 5 quarters.
Sabby Management's Parnell Pharmaceuticals Holdings Ltd position peaked at $635K in Q2 2016.
2 funds tracked by Wall St. Rank held Parnell Pharmaceuticals Holdings Ltd as of Q3 2017.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.